Status:
COMPLETED
The Role of Oxytocin and Interoception in Functional Neurological Disorder
Lead Sponsor:
University of Fribourg
Collaborating Sponsors:
Insel Gruppe AG, University Hospital Bern
Conditions:
Functional Neurological Disorder
Eligibility:
All Genders
18+ years
Brief Summary
The main goal of this project is to better understand the role of oxytocin and Interoception in FND. More specifically oxytocin's association with precision weighing, prediction errors and priors in t...
Detailed Description
The primary objective is to explore interoceptive processing during a behavioural (interoceptive) tasks and its association to the oxytocin (OT) system in patients affected by a functional neurologica...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Patients:
- A diagnosis of FND according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) diagnostic criteria
- Capable of judgement
- Willing to participate in the study (by signing the informed consent form)
- Inclusion Criteria for Healthy controls:
- Capable of judgement
- Willing to participate in the study (by signing the informed consent form)
- Exclusion Criteria for Patients:
- Presence of comorbid disorders such as psychosis or major depression with suicidal risk
- History of actual or suspected epilepsy
- Past surgery in the brain
- Cardio-vascular disease
- Implanted Investigational Medicinal Products (e.g. cochlear implants, neurostimulators, cardiac pacemakers)
- History of alcohol or drug abuse
- For female participants: breastfeeding, pregnancy (a standard urine pregnancy test will be provided)
- \<6h prior application prostaglandin
- Long QT-syndrome
- Inability to follow the procedures of the study, e.g. due to language problems
- Exclusion Criteria for Healthy controls:
- History of actual or suspected epilepsy
- Past surgery in the brain
- Cardio-vascular disease
- Implanted Investigational Medicinal Products (e.g. cochlear implants, neurostimulators, cardiac pacemakers)
- History of alcohol or drug abuse
- For female participants: breastfeeding, pregnancy (a standard urine pregnancy test will be provided)
- \<6h prior application prostaglandin
- Long QT-syndrome
- Inability to follow the procedures of the study, e.g. due to language problems
Exclusion
Key Trial Info
Start Date :
October 5 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 24 2025
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT06084325
Start Date
October 5 2023
End Date
January 24 2025
Last Update
March 27 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Inselspital
Bern, Canton of Bern, Switzerland, 3010
2
University of Fribourg
Fribourg, Canton of Fribourg, Switzerland, 1700